Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
Thromboembolism in multiple myeloma (MM) patients remains a common complication that renders the optimization of our thromboprophylaxis practice necessary. This review aims to make clear the need for the development of more accurate risk assessment tools and means of thrombosis prevention. Current c...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/1/191 |
| _version_ | 1797708208601563136 |
|---|---|
| author | Despina Fotiou Maria Gavriatopoulou Evangelos Terpos |
| author_facet | Despina Fotiou Maria Gavriatopoulou Evangelos Terpos |
| author_sort | Despina Fotiou |
| collection | DOAJ |
| description | Thromboembolism in multiple myeloma (MM) patients remains a common complication that renders the optimization of our thromboprophylaxis practice necessary. This review aims to make clear the need for the development of more accurate risk assessment tools and means of thrombosis prevention. Current clinical practice is guided by available guidelines published by the IMWG in 2014, but the extent to which these are implemented is unclear. Recently, several groups developed clinical scores for thrombosis risk in MM in an attempt to improve risk stratification, but these have not been validated or used in clinical practice so far. Research in this field is increasingly focusing on understanding the unique coagulation profile of the MM patient, and data on potential biomarkers that accurately reflect hypercoagulability is emerging. Finally, promising evidence on the effectiveness of direct oral anticoagulants (DOACs) in the context of thrombosis prevention in MM patients is increasingly becoming available. The critical appraisal of the above research areas will establish the necessity of combining disease-specific clinical risk factors with coagulation biomarkers to allow more effective risk stratification that will eventually lead to the reduction of this significant complication. Results from ongoing clinical trials on the role of DOACs are much anticipated. |
| first_indexed | 2024-03-12T06:19:01Z |
| format | Article |
| id | doaj.art-b03f3ba7021a4955883553de59671374 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:19:01Z |
| publishDate | 2020-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-b03f3ba7021a4955883553de596713742023-09-03T02:24:12ZengMDPI AGCancers2072-66942020-01-0112119110.3390/cancers12010191cancers12010191Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction ToolsDespina Fotiou0Maria Gavriatopoulou1Evangelos Terpos2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, 11528 Athens, GreeceDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, 11528 Athens, GreeceThromboembolism in multiple myeloma (MM) patients remains a common complication that renders the optimization of our thromboprophylaxis practice necessary. This review aims to make clear the need for the development of more accurate risk assessment tools and means of thrombosis prevention. Current clinical practice is guided by available guidelines published by the IMWG in 2014, but the extent to which these are implemented is unclear. Recently, several groups developed clinical scores for thrombosis risk in MM in an attempt to improve risk stratification, but these have not been validated or used in clinical practice so far. Research in this field is increasingly focusing on understanding the unique coagulation profile of the MM patient, and data on potential biomarkers that accurately reflect hypercoagulability is emerging. Finally, promising evidence on the effectiveness of direct oral anticoagulants (DOACs) in the context of thrombosis prevention in MM patients is increasingly becoming available. The critical appraisal of the above research areas will establish the necessity of combining disease-specific clinical risk factors with coagulation biomarkers to allow more effective risk stratification that will eventually lead to the reduction of this significant complication. Results from ongoing clinical trials on the role of DOACs are much anticipated.https://www.mdpi.com/2072-6694/12/1/191multiple myelomavenous thromboembolismrisk assessment modelsthromboprophylaxisdirect oral anticoagulants |
| spellingShingle | Despina Fotiou Maria Gavriatopoulou Evangelos Terpos Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools Cancers multiple myeloma venous thromboembolism risk assessment models thromboprophylaxis direct oral anticoagulants |
| title | Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools |
| title_full | Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools |
| title_fullStr | Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools |
| title_full_unstemmed | Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools |
| title_short | Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools |
| title_sort | multiple myeloma and thrombosis prophylaxis and risk prediction tools |
| topic | multiple myeloma venous thromboembolism risk assessment models thromboprophylaxis direct oral anticoagulants |
| url | https://www.mdpi.com/2072-6694/12/1/191 |
| work_keys_str_mv | AT despinafotiou multiplemyelomaandthrombosisprophylaxisandriskpredictiontools AT mariagavriatopoulou multiplemyelomaandthrombosisprophylaxisandriskpredictiontools AT evangelosterpos multiplemyelomaandthrombosisprophylaxisandriskpredictiontools |